S.O.S. Drug Policy Newsletter & Legislative Updates

Sorry, pot pushers - your "medical marijuana" is still a Schedule 1 controlled substance. In a recent press release, the Drug Enforcement Administration (DEA) confirmed the dangers of allowing marijuana to be grown and used freely. Indeed, the detrimental health effects that come from a lack of regulation overshadow the "medicinal" benefits of marijuana...

Published by The White House Statement by the President on the Comprehensive Addiction and Recovery Act of 2016 Today, I signed S.524, the Comprehensive Addiction and Recovery Act of 2016 into law. This legislation includes some modest steps to address the opioid epidemic. Given the scope of this crisis, some action is better than none.…

Insys Therapeutics, Inc. (INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys' dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is currently awaiting scheduling by the U.S. DEA...

It comes as no surprise that the prevalence of marijuana use has significantly increased over the last decade. With marijuana legal for recreational use in four states and the District of Columbia and for medical use in an additional 31 states, the public perception about marijuana has shifted, with more people reporting that they support legalization. However, there is little public awareness...